UBS Group AG Grows Holdings in Haleon PLC Sponsored ADR $HLN

UBS Group AG grew its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 107.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 995,987 shares of the company’s stock after acquiring an additional 515,670 shares during the period. UBS Group AG’s holdings in Haleon were worth $10,069,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of America Corp DE raised its stake in shares of Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Haleon by 36.6% in the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after purchasing an additional 3,207,986 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of Haleon in the third quarter valued at approximately $45,593,000. Raymond James Financial Inc. grew its holdings in shares of Haleon by 14.3% in the third quarter. Raymond James Financial Inc. now owns 4,931,464 shares of the company’s stock valued at $44,235,000 after purchasing an additional 616,284 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Haleon by 29.4% in the third quarter. Qube Research & Technologies Ltd now owns 3,124,287 shares of the company’s stock valued at $28,025,000 after purchasing an additional 710,259 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Trading Up 0.5%

NYSE HLN opened at $8.96 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The stock has a market capitalization of $39.81 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 2.04 and a beta of 0.15. The firm has a 50 day moving average of $9.74 and a two-hundred day moving average of $9.96.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The firm had revenue of $3.65 billion for the quarter. As a group, research analysts expect that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Announces Dividend

The company also recently declared a dividend, which was paid on Thursday, May 14th. Shareholders of record on Friday, April 10th were issued a dividend of $0.1307 per share. This represents a yield of 266.0%. The ex-dividend date was Friday, April 10th. Haleon’s payout ratio is 64.10%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on HLN shares. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Argus upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.40.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.